CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus | Lupus Science & Medicine

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Clinical Trials

CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Merrill JT, Furie R, Werth VP, et al

CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus

Lupus Science & Medicine 2016;3:doi: 10.1136/lupus-2016-000179.75